STOCK TITAN

Moderna cuts loan interest margins by 0.75 points

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Moderna, Inc. (MRNA) amended its Credit and Guaranty Agreement with Ares Capital Corporation, as administrative agent and collateral agent, and participating lenders, effective November 9, 2026. The amendment reduces applicable interest rate margins for initial term loans and delayed draw term loans by 0.75 percentage points: from 5.50% to 4.75% per annum for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate, and from 4.50% to 3.75% per annum for base-rate loans.

The amendment extends the maturity date for those loans from November 24, 2030 to November 24, 2031. It also extends availability for the first $400 million of delayed draw term loan commitments from November 24, 2027 to November 24, 2029, and for the remaining $500 million from November 24, 2028 to November 24, 2029. Both availability periods remain subject to earlier termination under the Credit Agreement.

Filing Explained

The amended delayed-draw commitments remain conditional: each borrowing is subject to the Credit Agreement’s conditions, so the extension provides continued access to borrowing capacity, not an assurance that funds can be drawn without satisfying those conditions.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Forward-looking term-rate margin 5.50% to 4.75% per annum Initial and delayed draw term loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate; reduced by 0.75 percentage points
Base-rate margin 4.50% to 3.75% per annum Initial and delayed draw term loans bearing interest based on the base rate; reduced by 0.75 percentage points
Loan maturity November 24, 2030 to November 24, 2031 Maturity date for the initial and delayed draw term loans
First delayed-draw commitment tranche $400 million Availability extended from November 24, 2027 to November 24, 2029
Remaining delayed-draw commitment tranche $500 million Availability extended from November 24, 2028 to November 24, 2029
Secured Overnight Funding Rate financial
"forward-looking term rate derived from the Secured Overnight Funding Rate"
The secured overnight funding rate (SOFR) is the interest rate banks pay to borrow cash overnight when the loan is backed by U.S. Treasury securities. Think of it as the overnight “rent” for cash secured by the safest government bonds; it is calculated from real transactions so it reflects actual short-term funding costs. Investors watch SOFR because it serves as a benchmark for loans, bonds and derivatives and therefore helps determine borrowing costs, yields and valuations across financial markets.
delayed draw term loan commitments financial
"first $400 million of delayed draw term loan commitments"
A delayed draw term loan commitment is a lender's promise to make one or more fixed-term loans that a borrower can take later during a specified availability period, subject to agreed conditions, documentation and any covenant tests. For investors, it shows a company’s access to committed future cash — like a scheduled credit tap — which affects liquidity, plans to refinance or fund growth and the timing of increased leverage or covenant triggers.
collateral security financial
"including its guarantees and collateral security"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How did Moderna’s loan interest margins change?

The amendment reduced applicable margins by 0.75 percentage points: from 5.50% to 4.75% per annum for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate, and from 4.50% to 3.75% per annum for base-rate loans.

When do Moderna’s loans mature, and how long are delayed-draw commitments available?

The maturity date moved from November 24, 2030 to November 24, 2031. Availability for the first $400 million of delayed draw term loan commitments was extended to November 24, 2029, and availability for the remaining $500 million was extended to November 24, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001682852false00016828522026-11-092026-11-09

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 9, 2026

MODERNA, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3875381-3467528
 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
 
325 Binney Street
Cambridge, MA
02142
(Address of principal executive offices)(Zip code)

Registrant’s telephone number, including area code: (617) 714-6500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareMRNAThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company      ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ☐




Item 1.01.    Entry into a Material Definitive Agreement.

On November 9, 2026, Moderna, Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to its Credit and Guaranty Agreement, dated as of November 19, 2025 (the “Credit Agreement”), among the Company, as borrower, the guarantor subsidiaries from time to time party thereto, the lenders from time to time party thereto and Ares Capital Corporation, as administrative agent and collateral agent. The Amendment was entered into by the Company, Ares Capital Corporation and the lenders party thereto and became effective on November 9, 2026.

The Amendment reduces the applicable interest rate margins for the initial term loans and delayed draw term loans by 0.75 percentage points, from 5.50% to 4.75% per annum for loans bearing interest at a forward-looking term rate derived from the Secured Overnight Funding Rate and from 4.50% to 3.75% per annum for loans bearing interest based on the base rate. The Amendment also extends the maturity date for those loans from November 24, 2030 to November 24, 2031.

The Amendment extends the availability period for the first $400 million of delayed draw term loan commitments from November 24, 2027 to November 24, 2029 and for the remaining $500 million of delayed draw term loan commitments from November 24, 2028 to November 24, 2029, in each case, subject to earlier termination in accordance with the Credit Agreement. Borrowings of delayed draw term loans remain subject to the applicable conditions under the Credit Agreement. Except as modified by the Amendment, the Credit Agreement remains in effect, including its guarantees and collateral security.

The above summary of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 2.03.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure set forth in Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 2.03 by reference.
Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No.  Description
10.1  
Amendment No. 1 to Credit and Guaranty Agreement, dated as of November 9, 2026, by and among Moderna, Inc., Ares Capital Corporation and the lenders party thereto.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                                
Date: November 16, 2026
MODERNA, INC.
By:/s/ James M. Mock
James M. Mock
Chief Financial Officer



Filing Exhibits & Attachments

4 documents

Keep reading